Disc Medicine, Inc. Shareholders' Equity
Disc Medicine, Inc. (IRON) had Shareholders' Equity of $644.16 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-30
- 2026-06-30: Stockholders' Equity Attributable to Parent $644.16M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $688.43M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $739.83M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $573.39M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $644.16M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $688.43M 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $739.83M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $573.39M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $614.16M 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $660.36M 10-Q · filed 2026-07-30 | |
| 2024-12-31 | $443.59M 10-Q · filed 2026-07-30 | |
| 2024-09-30 | $467.96M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $488.83M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $338.07M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $345.12M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $358.97M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $371.22M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $232.85M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $176.60M 10-K · filed 2026-02-26 | |
| 2022-09-30 | -$98.53M 10-Q · filed 2023-11-09 | $104.57M 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$82.78M 10-Q · filed 2023-11-09 | $106.90M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$73.67M 10-Q · filed 2023-11-09 | $111.61M 10-Q · filed 2022-05-06 |
| 2021-12-31 | -$64.20M 10-K · filed 2024-03-21 | $124.84M 10-K · filed 2022-03-10 |
| 2021-09-30 | $140.86M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $157.68M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $171.16M 10-Q · filed 2022-11-10 | |
| 2020-12-31 | -$28.81M 10-K · filed 2023-03-31 | $5.00M 10-K · filed 2021-03-29 |
| 2020-09-30 | -$8.28M 10-Q · filed 2021-11-15 | $5.00M 10-Q · filed 2020-11-12 |
| 2020-06-30 | -$6.62M 10-Q · filed 2021-11-15 | $23.50K 10-Q · filed 2020-11-12 |
| 2020-03-31 | $10.00K 10-Q · filed 2021-11-15 | |
| 2019-12-31 | -$10.43M 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |